Late human gestation is associated with an increase in the concentration of cortisol (F) in the fetal circulation and amniotic fluid. It had been assumed that most of the F measured in the amniotic fluid came from the fetal adrenal gland. However, local production of F can also occur in human intrauterine tissues from inactive cortisone under the influence of the enzyme 11␤-hydroxysteroid dehydrogenase (11␤-HSD) type 1. Recent studies have shown that 11␤-HSD 1 activity is up-regulated by prostaglandins (PG) E2 and F2␣, hormones that are produced in the fetal membranes (FM) at term. In the present study, we hypothesized that 11␤-HSD 1 expression would increase in FM during pregnancy and at labor, creating the potential for local increase in F production at term. We ex- 
T HE CONCENTRATION OF cortisol (F) in amniotic fluid
increases during pregnancy in humans (1, 2) , rhesus monkeys (3), and sheep (4) . In late gestation, F plays a major role in the maturation of different fetal organs such as lung, liver, and gastrointestinal tract (5) , and it contributes to the onset of labor by increasing prostaglandin (PG) output (6) . The majority of F present in the amniotic fluid at term apparently reflects production by the fetal adrenal (7) , but the fetal membranes may be an extraadrenal intrauterine source of the steroid (8, 9) . F and its biologically inactive metabolite cortisone (E) are interconverted through the enzyme 11␤-hydroxysteroid dehydrogenase (11␤-HSD) (10) . Two distinct isozymes of 11␤-HSD, known as 11␤-HSD 1 and 11␤-HSD 2, have been characterized and cloned (10) . 11␤-HSD 1 possesses both oxidase (F to cortisone) and reductase (cortisone to F) activities. This enzyme has a higher affinity for cortisone than for F (11) (12) (13) and operates predominantly in a reductase direction. In contrast, 11␤-HSD 2 under physiological conditions exhibits only oxidase activity and has much higher affinity for F. The 11␤-HSD 2 has been localized to placental syncytiotrophoblast (14) , whereas 11␤-HSD 1 is expressed predominantly in human placental intermediate trophoblast cells, vascular endothelium, and more abundantly in chorion trophoblast cells, amnion, and decidua (15) . Placental 11␤-HSD 2 influences the transplacental transfer of F, but the role played by 11␤-HSD 1 in the fetal membranes is still to be determined. In recent studies from our laboratory, we confirmed the predominance of 11␤-HSD 1 reductase over dehydrogenase activity in chorion trophoblast cells and showed that the reductase activity increased in response to PGF2␣ and PGE2 stimulation (16) . Activation of 11␤-HSD 1 may contribute to local F production within the fetal membranes, which in turn increases PG production by activating the PG synthesizing enzymes and inhibiting the PG metabolism (17, 18) . These findings led us to hypothesize that there might be an increase during late gestation and labor in 11␤-HSD 1 expression within the fetal membranes. Therefore, in the present study, we examined expression and reductase activity of 11␤-HSD 1 in the placenta, chorion, and amnion during late human gestation and with respect to the labor process.
Sinai Hospital (Toronto, Canada) and the University of Toronto. Placentae (n ϭ 30) were collected at preterm no labor (26 -36 wk) , term no labor (38 -41 wk), and term with labor. The indications for the preterm nonlaboring patients in this study included antepartum hemorrhage, cervical cancer, and multiple pregnancy. There were no clinical or pathological signs of preeclampsia or other placental disease. Term human placentae were obtained from uncomplicated pregnancies after elective cesarean section and after spontaneous labor.
11␤-HSD 1 expression
Immunohistochemical analysis (IHC). Fetal membranes: Rolls of fetal membranes were embedded in paraffin, sectioned at 5 m on a microtome (Histocut, Reichert-Jung, Cambridge Instruments, Heidelberg, West Germany), placed on Superfrost Plus slides (Fisher Scientific, Fair Lawn, NJ), and processed for immunohistochemistry as described (16) . Briefly, slides were incubated in xylene substitute (BD Diagnostic Systems, Franklin Lakes, NJ) to remove the paraffin and then rehydrated in a graded series of ethanol dilutions and a final 0.01 m PBS [pH 7.4; 150 mm NaCl, 19 mm Na 2 HPO 4 , 1.5 mm NaH 2 PO 4 ] wash. Slides were then incubated with rabbit antisheep 11␤-HSD 1 antibody (1:500 dilution in PBS) (19) . The avidin-biotin-peroxidase technique (Vectastain ABC Kit; Vector Laboratories, Burlingame, CA) for immunostaining was used with diaminobenzidine (Sigma, St. Louis, MO) as the substrate. Slides were counterstained with Carazzi's hemotoxylin, followed by dehydration in a graded series of ethanols, cleared in xylene substitute, and mounted with permount (Fisher Scientific). To test the specificity of the antibody, fetal membranes were also stained with primary antibody preabsorbed with excess immunizing peptide (19) .
IHC. Placenta: Staining was performed according to the same protocol described above, except that an antigen retrieval technique was applied to enhance detection of 11␤-HSD 1 protein (20) . Before adding the primary antibody, placental sections were placed in Coplin jars containing 10 mm citrate buffer (pH 6.0; Sigma) and placed in a microwave oven at 96 C for 20 min. After cooling for 40 min, sections were washed in PBS, preincubated for 30 min in 5% normal goat serum, and then incubated overnight at 4 C with primary antibody (1:250 dilution).
Western blot analysis. Frozen fetal membrane samples were homogenized on ice for 1 min in RIPA lysis buffer [50 nm Tris HCl (pH 7.5), 150 mm NaCl, 1% (wt/vol) sodium deoxycholate, 0.1% sodium dodecyl sulfate, 100 mm sodium orthovanadate (Sigma), 1% (vol/vol) Triton X-100 (Fisher Chemicals), and Complete MiniEDTA-free protease inhibitors (Roche Molecular Biochemicals, Dorval, Canada)]. Homogenates were centrifuged (4 C at 15,000 ϫ g) for 15 min, and supernatants were collected. Protein concentrations were determined by the Bradford assay (21) . Polyacrylamide gels were prepared (stacking gel, 4%; separating gel, 12% for 11␤-HSD 1). Proteins (50 g/well) were separated by PAGE and then transferred electrophoretically to a 0.45-m pore nitrocellulose membrane (Bio-Rad Laboratories, Inc., Hercules, CA). Transfer was confirmed by protein visualization with Ponceau S (Sigma). Blots were washed with PBS-T [150 mm NaCl, 10 mm Na 2 HPO 4 , 1.5 mm NaH 2 PO 4 , and 0.1% Tween-20 (Sigma); pH 7.5] and incubated overnight with blocking solution (5% skim milk powder in PBS-T). Subsequently, blots were incubated with primary antibody for rabbit antisheep 11␤-HSD 1 (1:1000 dilution in blocking solution) for 1 h. Blots were then rinsed six times for 5 min each with PBS-T and incubated with secondary rabbit antiserum conjugated with horseradish peroxidase (1:3000 dilution in blocking solution; Amersham Pharmacia Biotech, Piscataway, NJ) for 1 h. Blots were washed six times, 5 min each, and the antibody-antigen complex was detected using the Amersham Pharmacia Biotech ECL detection system (Amersham Pharmacia Biotech). The membranes were then exposed to X-OMAT blue film (Kodak Scientific Imaging Products, Rochester, NY). A major band of 34 kDa, corresponding to the known molecular mass of 11␤-HSD 1, was clearly visible in all specimens tested. A second band of 32 kDa, corresponding to the nonglycosylated form of 11␤-HSD 1, was also visible in some specimens. The intensities of immunoreactive bands were measured by scanning (6200C scanner, Hewlett Packard (Canada) Ltd., Mississauga, Ontario, Canada) and analyzing the image on a desktop computer using Scion Image software (v.4.0.2; Scion Corporation, Frederick, MD). The mean pixel density for each band was analyzed to obtain relative OD units for 11␤-HSD 1 protein. To standardize for sample loading, the relative OD units of 11␤-HSD 1 for each band were standardized to the relative OD units of the total protein in the band as analyzed by Ponceau S (Bio-Rad Laboratories, Inc.). To compare measurements between blots prepared at different times, a reference sample from human placenta was included in each gel.
11␤-HSD 1 activity
Reagents and supplies. [1, 2, 6, Tissue homogenate from each sample was centrifuged at 4 C at 790 ϫ g for 10 min, and the supernatant was then centrifuged at 4 C at 25,000 ϫ g for 40 min. This supernatant was centrifuged at 4 C at 110,000 ϫ g for 60 min, and the pellet containing the microsomal fraction was resuspended in 200 -300 l 11␤-HSD1 homogenization buffer. The protein content was measured by the Bradford method using a protein assay kit (Bio-Rad) with BSA as standard (21 Ϫ3 m) at 37 C for 10 min. The reaction was stopped by immediate transfer of the tubes to ice and addition of ethyl acetate (750 l in a final volume of 1 ml; Sigma). The steroids were extracted using ethyl acetate and separated on silicon-coated thin-layer chromatography (TLC) plates (Fisher Scientific) using the solvent system chloroform/ ethanol (95:5, vol/vol). Radioactivity was counted using a ␤-counter. 11␤-HSD1 activity was expressed as picomoles of F formed per milligram of microsomal protein per minute. The percentage conversion of E to F was always less than 15%. Under these conditions the enzyme activity was not limited by substrate availability.
Statistical analysis
Results are expressed as the mean Ϯ sem. Statistical comparisons were made using one-way ANOVA test (␣ ϭ 0.05) (SigmaStat, Jandel Scientific Software, San Rafael, CA).
Results

11␤-HSD 1 expression in late gestation in the fetal membranes
Sections of normal human fetal membranes at 26 wk gestation stained with anti-11␤-HSD 1 antibody revealed specific staining in the chorion trophoblast layer and amnion epithelial cells. The intensity of the staining in chorion increased during pregnancy and reached a maximum at term (Fig. 1A) . Western blotting analysis of proteins from human fetal membranes homogenate confirmed the presence of 11␤-HSD 1, which was detected as a major band at 34 kDa. The amount of 11␤-HSD 1 protein in the homogenates increased with advancing gestation and was significantly greater (P Ͻ 0.05) at term than at any other gestational age examined (Fig. 1B) .
11␤-HSD1 activity during late gestation in the fetal membranes
11␤-HSD 1 reductase activity was measured in the microsomal fraction of fetal membranes from 18 patients at gestational ages ranging from 26 wk gestation to term. Protein (20 g) was incubated for 10 min with E (1 m) in the presence of 1 mm NADPH. These conditions were chosen so that the 11␤-HSD 1 reductase activity was measured in the linear range of the initial velocity and a maximum of 15% substrate was transformed at the end of the reaction. The 11␤-HSD 1 activity increased gradually from the first age bracket (26 -30 wk) to term; however, the increase was only significant at term compared with each of the other age groups (Fig. 2) . There was more than a 2-fold increase in 11␤-HSD 1 reductase activity, confirming our finding of increased 11␤-HSD 1 protein expression.
Effect of labor on 11␤-HSD1 expression in human amnion and chorion
The effect of labor on 11␤-HSD 1 expression in chorion and amnion tissue was examined from six nonlaboring patients and six patients in labor, using immunohistochemistry and Western blot analysis. Immunoreactive 11␤-HSD 1 was localized to amnion, chorion, and decidua. The intensity of the staining in both chorion and amnion was higher in the laboring group compared with the nonlabor group (Fig. 3A) . 11␤-HSD1 protein levels increased in both chorion (P ϭ 0.06) and amnion (P Ͻ 0.05) with labor (Fig. 3B) .
11␤-HSD 1 expression during late gestation in the placenta
11␤-HSD 1 is also present in the human placenta. Previously, we found that the enzyme was localized mainly to intermediate trophoblast and blood vessels (15) . This expression at both protein and mRNA levels was significantly lower than the expression of the type 2 11␤-HSD (15 also present in the syncytiotrophoblast (Fig. 4A) . However, the expression of 11␤-HSD 1 was significantly lower in placenta compared with the amnion and chorion (Fig. 4B ). There was no gestational age-related change in placental 11␤-HSD 1 protein, in contrast to the increase in the 11␤-HSD 1 expression observed in the fetal membranes (Fig. 5) .
Discussion
The 11␤-HSD 1 and 2 enzymes play a crucial role in modulating corticosteroid hormone action at a prereceptor level. Although 11␤-HSD 1 was the first of these enzymes to be characterized and cloned in rodent and human tissues (22, 23) , there has recently been more interest in the 11␤-HSD 2 isozyme, principally because of its role in protecting the fetus from glucocorticoid excess during pregnancy and its association with hypertension (24) . Several studies, however, have indicated that 11␤-HSD 1 regulates glucocorticoid hormone availability in key tissues, such as the liver, gonad, pituitary, brain, and adipose tissues (25, 26) . 11␤-HSD 1 activity is bidirectional, at least in tissue homogenates with exogenous cofactor added. However, 11␤-HSD 1 acts predominantly as a reductase in intact cell assays (12, 27) and in human fetal membranes (16, 28) , generating active F from its E. We have shown recently that in human chorion trophoblast cells, 11␤-HSD 1 is up-regulated by PGE2 and PGF2␣ (16) . Production of these eicosanoids is well recognized as a critical step in the processes leading to parturition. Their synthesis is stimulated by glucocorticoids, and their interaction with 11␤-HSD 1 creates a short loop feed-forward loop within chorion (16) . In the present study, we demonstrated that both expression and activity of the enzyme 11␤-HSD 1 increases in human fetal membranes during late gestation, with the most significant changes occurring at term. These data are consistent with previous reports describing the chorionic membrane as an extraadrenal source of fetal F in human amniotic fluid (9) and suggest that 11␤-HSD 1 is likely the key enzyme responsible for this extraadrenal source. Our results also show that 11␤-HSD 1 expression increases in amnion and chorion tissues with labor. However, this increase was only significant in amniotic tissue. This difference might be explained by variation in the local stimulation of 11␤-HSD1 by PGs in the fetal membranes (16) . The chorion is a major site of PG inactivation due to the presence of the enzyme PG dehydrogenase (PGDH), whereas amnion is essentially the site of increased PG synthesis due to the expression of PG synthesizing enzymes without PGDH. Hence, elevations in PG output may be greater in amnion than chorion, and these tissues may constitute two different environments for 11␤-HSD 1 regulation by PGs.
The present study suggests that in the fetal membranes 11␤-HSD1 may be facilitatory to the integrated cellular regulation between glucocorticoids and PGs. 11␤-HSD 1 is discretely colocalized in chorion trophoblast cells with PGH synthase 2 and PGDH, consistent with paracrine/autocrine regulation between glucocorticoids and PGs. We speculate that the increase of 11␤-HSD 1 in late gestation, and with the onset of labor in human fetal membranes to generate active F, could have more general applicability in these tissues. For example, glucocorticoids stimulate CRH output in human chorion and placental trophoblast (29) . CRH is discretely elevated in patients presenting in preterm labor at 28 -32 wk who go on to deliver prematurely (30) . Feed forward effect of PG to increase 11␤-HSD 1 in chorion (16) or to decrease 11␤-HSD 2 in placenta (31) would create an environment of increased local F with potential for enhanced stimulation of CRH output. We speculate that these relationships, combined with a reduction of placental 11␤-HSD 2 expression with lowered oxygenation (32) , may contribute to the associations between elevated cord blood CRH in intrauterine growth restricted pregnancies, the inhibition effects of F of fetal growth, and the higher predisposition of these pregnancies to preterm delivery (33) Many groups have reported that the F:E ratio in amniotic fluid increases significantly throughout gestation, with the greatest change after 30 wk of pregnancy. At term, the amniotic fluid F:E ratio is higher than that of the cord serum (34) . In late gestation, F present in the amniotic fluid comes from at least two sources: the fetal adrenals, which generate largely conjugated F from the transitional cortex, and the fetal membranes, which produced unconjugated F (35) . Most authors have found significant correlations between total F in amniotic fluid and parameters of lung maturation (36) . The local increase in expression and activity of the 11␤-HSD 1 enzyme, potentially increasing local F, emphasizes the importance of the physiological role that this enzyme might play during late gestation. Although we have focused on the potential intrauterine actions of the locally produced F, it remains possible that this steroid also reaches the fetus through the chorionic vasculature and amniotic fluid.
In the fetal membranes, 11␤-HSD 1 acts mainly as a reductase. Dehydrogenase activity can also be detected, but only if some adherent decidual tissue is present in the sample, because decidual 11␤-HSD 1 exhibits mainly dehydrogenase activity (15) . Therefore, decidual tissue was removed as completely as possible at the time of tissue collection from all samples used in the present study. Substantial 11␤-HSD 1 was reported to be present in human placenta. Here, the enzyme might act as a dehydrogenase along with the type 2 11␤-HSD (37), which is the predominant enzyme type in the syncytiotrophoblast (15, 28) . Previously, we (15) and others (14) reported only low 11␤-HSD 1 immunoreactivity by IHC, although Pepe and Albrecht (38) had clearly shown that the enzyme was present. This apparent discrepancy was reconciled by use of antigen retrieval procedures, allowing us to demonstrate clearly the presence of 11␤-HSD 1 protein in the syncytiotrophoblast and confirming the original observations of Pepe and Albrecht (38) . However, Western blotting revealed that the level of 11␤-HSD 1 protein in the placenta was much less than that in the chorion and amnion and did not change with gestation. It remains possible that altered subcellular localization of this enzyme in placental tissue affects its biological activity (37), but we have not examined this option further. Clearly, the increase in 11␤-HSD 1 protein in late pregnancy and at term is peculiar to the membranes, consistent with a physiological role at that locale.
In summary, the results of the present study show that 11␤-HSD 1 is present and active in human fetal membranes from 26 wk gestation to term and that both activity and expression increase gradually in late gestation and further at the time of labor. Consequently, the final regulation and local availability of glucocorticoid in the membranes and amniotic fluid may depend upon normal expression of 11␤-HSD1 and its local regulation. 
